Citations

Clear

949 citation(s) found for "Li, Bryan".

Surgical Site Infections in Cancer Patients with Intrathecal Drug Delivery Devices
Scanlon, Maura M., Gazelka, Halena M. , Moeschler, Susan M. , Hoelzer, Bryan C. , Hooten, W. Michael , Bendel, Markus A. , Lamer, Tim J.

Mayo Clinic

Pain Medicine | August 22, 2016 | Volume: 18 | Issue: 3 | Pages: 520-525

10.1093/pm/pnw203 | PMID 27550951 Get It

Abstract Objectives. Our purpose was to determine the incidence of surgical site infection (SSI) in cancer patients receiving an intrathecal drug delivery system (IDDS) and compare that rate with the incidence of SSI in the general population receiving an IDDS or spinal cord stimulator. We attempted to describe risk factors for SSIs in cancer patients treated with IDDS in terms of exposure to cancer treatments. Design. Retrospective review. Setting. Large tertiary care center. Patients. Cancer patients receiving an IDDS in 2006–2013. Methods. The incidence of SSI was determined according to the US Centers for Disease Control and Prevention definition. Medication regimens and current cancer treatment were investigated to identify immunocompromised patients during IDDS placement. Microbacteriology, treatment, and overall outcomes were investigated. Results. Sixty-four patients had an IDDS implanted in 2006–2013. SSI developed in four patients (6.2%). All four patients had received chemotherapy or radiotherapy within three months before implantation. Three of the three were receiving dexamethasone, and three of the four required explantation of the IDDS. Conclusion. The incidence of SSI was at the upper end of the published infection rates for IDDS. The risk of SSI may be increased in this population because of factors that alter the patient’s immune status, including concomitant corticosteroid use, radiotherapy near the SSI, and presence of immunomodulators. The identification and mitigation of certain risk factors for this population may prevent infection in future patients.
Sudden cardiac death and late arrhythmias after the Fontan operation
Pundi, Kavitha N., Pundi, Krishna , Johnson, Jonathan N. , Driscoll, David J. , Wackel, Philip L. , Cetta, Frank , Cannon, Bryan C. , Li, Zhuo , Pundi, Krishna N, Dearani, Joseph A. , Li, Zhuo Ya , McLeod, Christopher J. , Pundi, Krishna

Mayo Clinic

Congenital Heart Disease | August 22, 2016 | Volume: 12 | Issue: 1 | Pages: 17-23

10.1111/chd.12401 | PMID 27545004 Get It

Treatment of Refractory Postdural Puncture Headache after Intrathecal Drug Delivery System Implantation with Epidural Blood Patch Procedures: A 20-Year Experience
Bendel, Markus A. , Moeschler, Susan M. , Qu, Wenchun , Hanley, Eugerie, Neuman, Stephanie, Eldrige, Jason S. , Hoelzer, Bryan C. , Neuman, Stephanie A

Mayo Clinic

Pain Research and Treatment | August 11, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-5

10.1155/2016/2134959 | PMID 27597897 Get It

A recent publication reported the incidence of postdural puncture headache (PDPH) in conjunction with intrathecal drug delivery system (IDDS) implantation to be nearly 23 percent. Many patients responded to conservative measures but a percentage needed invasive treatment with an epidural blood patch (EBP). There is limited data to describe the technical details, success rates, and complications associated with EBP in this population. This study aims to provide a retrospective report of EBP for patients suffering from PDPH related to IDDS implantation. A chart review established a cohort of patients that required EBP in relation to a PDPH after IDDS implantation. This cohort was evaluated for demographic data as well as details of the EBP including technical procedural data, success rates, and complications. All patients received a trial of conservative therapy. Standard sterile technique and skin preparation were utilized with no infectious complications. The EBP was placed below the level of the IDDS catheter in 94% of procedures. Fluoroscopy was utilized in each case. The mean EBP volume was 18.6 cc and median time of EBP was day 7 after implant. There were no complications associated with EBP. EBP appears to be an effective intervention in this subset of PDPH patients.
Association of Cognitive Performance with Time at Altitude, Sleep Quality, and Acute Mountain Sickness Symptoms
Issa, Amine, Herman, Nicole , Wentz, Robert J., Taylor, Bryan J. , Summerfield, Doug C., Johnson, Bruce D. , Issa, Amine N, Herman, Nicole M, Summerfield, Douglas T. , Taylor, Bryan J

Mayo Clinic

Wilderness & Environmental Medicine | July 24, 2016 | Volume: 27 | Issue: 3 | Pages: 371-378

10.1016/j.wem.2016.04.008 | PMID 27460198 Get It

Objective It is well documented that cognitive performance may be altered with ascent to altitude, but the association of various cognitive performance tests with symptoms of acute mountain sickness (AMS) is not well understood. Our objective was to assess and compare cognitive performance during a high-altitude expedition using several tests and to report the association of each test with AMS, headache, and quality of sleep. Methods During an expedition to Mount Everest, 3 cognitive tests (Stroop, Trail Making, and the real-time cognitive assessment tool, an in-house developed motor accuracy test) were used along with a questionnaire to assess health and AMS. Eight team members were assessed pre-expedition, postexpedition, and at several time points during the expedition. Results There were no significant differences ( P >.05) found among scores taken at 3 time points at base camp and the postexpedition scores for all 3 tests. Changes in the Stroop test scores were significantly associated with the odds of AMS ( P <.05). The logistic regression results show that the percent change from baseline for Stroop score (β = −5.637; P = .032) and Stroop attempts (β = −5.269; P = .049) are significantly associated with the odds of meeting the criteria for AMS. Conclusions No significant changes were found in overall cognitive performance at altitude, but a significant relationship was found between symptoms of AMS and performance in certain cognitive tests. This research shows the need for more investigation of objective physiologic assessments to associate with self-perceived metrics of AMS to gauge effect on cognitive performance.
Are Short-term Outcomes of Hip Arthroscopy in Patients 55 Years and Older Inferior to Those in Younger Patients?
Bryan, Andrew J., Krych, Aaron J. , Pareek, Ayoosh , Reardon, Patrick J., Berardelli, Rebecca L., Levy, Bruce A. , Berardelli, Rebecca, Krych, Aaron J

Mayo Clinic

The American Journal of Sports Medicine | July 14, 2016 | Volume: 44 | Issue: 10 | Pages: 2526-2530

10.1177/0363546516652114 | PMID 27416992 Get It

Background: Hip arthroscopy for young patients with femoroacetabular impingement (FAI) has been successful, but the efficacy of hip arthroscopy in older patients is not clearly defined. Purpose: To evaluate the clinical outcomes of patients 55 years and older who are undergoing hip arthroscopy and to compare outcomes with those of patients younger than 55 years. Study Design: Cohort study; Level of evidence, 3. Methods: A total of 201 (63 male, 138 female) patients undergoing primary hip arthroscopy for FAI without radiographic arthritis (Tönnis grade <3) were isolated from a prospective database and stratified by age to <55-year and ≥55-year groups. Patients were evaluated preoperatively and 1 and 2 years postoperatively using the modified Harris Hip Score (mHHS) and Hip Outcome Score (HOS: functional scores, as well as Activities of Daily Living [ADL] and Sport subscales). A Wilcoxon signed rank sum test was used to evaluate the differences in outcome scores between the cohorts at each interval. Results: The <55-year group included 174 patients (mean age, 37 ± 12 years), and the ≥55-year group included 27 patients (mean age, 61 ± 5 years). The minimum follow-up time was 2 years in each group. Preoperative Tönnis grades and mHHS scores (59 vs 59; P = .75) were similar between groups. The ≥55-year cohort underwent labral debridement more frequently (78% vs 36%; P =.02) and were more likely to have full-thickness cartilage defects (22% vs 4%; P = .04). Despite this, the mHHS in both groups improved significantly from baseline, without significant differences at 1 year (86 [≥55 years] vs 81 [<55 years]; P = .53) or 2 years (73.88 [≥55 years] vs 79.54 [<55 years]; P = .06). However, at a minimum 2-year follow-up, patients <55 years had significant improvements over patients ≥55 years in the HOS subscales for ADL score (85.6 vs 75.2; P = .03), ADL rating (80.1 vs 70.0; P = .004), Sport score (70.2 vs 55.6; P = .04), and Sport rating (70.2 vs 58.0; P = .04). Conclusion: Although younger patients had superior HOS outcomes reported at 2 years compared with older patients after hip arthroscopy for FAI, both groups had significant improvement compared with their baseline. These data suggest that carefully selected patients 55 years and older without radiographic arthritis may benefit from hip arthroscopy.
Impact of chronic systolic heart failure on lung structure-function relationships in large airways
Chase, Steven C. , Wheatley, Courtney M. , Olson, Lyle J. , Beck, Kenneth C., Wentz, Robert J., Snyder, Eric M., Taylor, Bryan J. , Johnson, Bruce D. , Taylor, Bryan J

Mayo Clinic

Physiological Reports | July 14, 2016 | Volume: 4 | Issue: 13 | Pages: e12867

10.14814/phy2.12867 | PMID 27418546 Get It

Perianesthetic Management of Patients With Thyroid-Stimulating Hormone–Secreting Pituitary Adenomas
Dyer, Matthew W., Gnagey, Amy, Jones, Bryan T., Pula, Roger D., Lanier, William L. , Atkinson, John L. D., Pasternak, Jeffrey J.

Mayo Clinic

Journal of Neurosurgical Anesthesiology | June 18, 2016 | Volume: 29 | Issue: 3 | Pages: 341-346

10.1097/ana.0000000000000325 | PMID 27322091 Get It

Background: Thyroid-stimulating hormone (TSH)–secreting pituitary adenomas are a rare cause of secondary hyperthyroidism. Anesthetic management of these patients has not been formally described in the literature. Materials and Methods: Patients who underwent resection of a TSH-secreting pituitary adenoma during 1987 to 2012 at a single institution were identified. Preoperative thyroid hormone state, anesthetic management, and outcome were recorded. Hemodynamic associations with intraoperative events were compared between those who were hyperthyroid and euthyroid at the time of surgery. Results: Of 2268 patients having transsphenoidal resection of a pituitary tumor, 19 (0.84%) had resection of a TSH-secreting adenoma. At the time of surgery, 6 (32%) were hyperthyroid, 11 (58%) were euthyroid, and 2 (10%) were hypothyroid based on serum thyroxine concentration. General anesthesia was maintained with a potent inhaled anesthetic in all patients, and included nitrous oxide in 18 of 19 (95%). Seventeen (90%) had an arterial catheter placed for surgery. Only 1 patient (5%) required an intraoperative blood transfusion. There were no significant differences in heart rate or blood pressure at induction of anesthesia, upon intranasal injection of local anesthetic containing epinephrine, or upon emergence from anesthesia, between patients who were chemically hyperthyroid or euthyroid. Twelve of 19 (63%) had tumor extension beyond the sella turcica. Common complications were nausea and vomiting (42%), diabetes insipidus (32%), and temporary or permanent hypopituitarism (42%). Conclusions: Patients having resection of TSH-secreting pituitary adenomas can present in any thyroid state. An awareness of risks and potential complications in patients with TSH-secreting adenomas can help tailor perioperative care.
Health Care Utilization and Direct Medical Costs of Tennis Elbow
Sanders, Thomas L. , Kremers, Hilal Maradit , Bryan, Andrew J., Ransom, Jeanine E. , Morrey, B.F. , Maradit Kremers, Hilal, Morrey, Bernard F, Maradit Kremers, Hilal

Mayo Clinic

Sports Health: A Multidisciplinary Approach | May 23, 2016 | Volume: 8 | Issue: 4 | Pages: 355-358

10.1177/1941738116650389 | PMID 27215568 Get It

Background: Tennis elbow is commonly encountered by physicians, yet little is known about the cost of treating this condition. Hypothesis: The largest cost associated with treating tennis elbow is procedural intervention. Study Design: Descriptive epidemiology study. Level of Evidence: Level 4. Methods: This retrospective population-based study reviewed patients who were treated for new-onset tennis elbow between January 1, 2003 and December 31, 2012. All patients were followed up through their medical and administrative records to identify health care encounters and interventions for tennis elbow. Unit costs for each health service/procedure were adjusted to nationally representative unit costs in 2013 inflation-adjusted dollars. Results: In a cohort of 931 patients who had 2 or more clinical encounters for new-onset lateral epicondylosis during a 12-month period after initial diagnosis, 62% received a median of 3 physical therapy sessions (cost, $100/session) and 40% received a median of 1 steroid injection (cost, $82/injection). Only 4% of patients received surgical intervention with mean costs of $4000. The mean (median) total direct medical cost of services related to lateral epicondylosis for the entire cohort was $660 ($402) per patient over the 1-year period after diagnosis. Patients who continued to be treated conservatively between 6 and 12 months after diagnosis incurred relatively low median costs of $168 per patient. Conclusion: In this cohort, a second encounter with a physician for tennis elbow was a strong predictor of increased treatment cost due to a higher likelihood of specialist referral, use of physical therapy, or treatment with steroid injection. Clinical Relevance: The majority of direct medical spending on tennis elbow occurs within the first 6 months of treatment, and relatively little expense occurs between 6 and 12 months after diagnosis unless a patient undergoes surgical intervention.
Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Silverberg, Mark S. , Satsangi, Jack, Ahmad, Tariq , Arnott, Ian , Bernstein, Çharles N. , Caprilli, R., Colombel, Jean–Frédéric, Gasché, Christoph , Geboes, Karel, Jewell, Derek P., Karban, Amir, Peña, A. S. , Riddell, Robert H. , Sachar, David B., Steinhart, A. Hillary , Targan, Stephan R. , Vermeire, Séverine , Warren, Bryan F., Bernstein, Charles Noah , Brant, Steven R , Loftus, Edward V. , Schreiber, Stefan , Vermeire, Séverine

Mayo Clinic

Canadian Journal of Gastroenterology | May 17, 2016 | Volume: 19 | Issue: suppl a | Pages: 5A-36A

10.1155/2005/269076 | PMID 16151544 Get It

The discovery of a series of genetic and serological markers associated with disease susceptibility and phenotype in inflammatory bowel disease has led to the prospect of an integrated classification system involving clinical, serological and genetic parameters. The Working Party has reviewed current clinical classification systems in Crohn’s disease, ulcerative colitis and indeterminate colitis, and provided recommendations for clinical classification in practice. Progress with respect to integrating serological and genetic markers has been examined in detail, and the implications are discussed. While an integrated system is not proposed for clinical use at present, the introduction of a widely acceptable clinical subclassification is strongly advocated, which would allow detailed correlations among serotype, genotype and clinical phenotype to be examined and confirmed in independent cohorts of patients and, thereby, provide a vital foundation for future work.
Sites of Successful Ventricular Fibrillation Ablation in Bileaflet Mitral Valve Prolapse Syndrome
Syed, Faisal F. , Ackerman, Michael J. , Mulpuru, Siva K. , Sriram, Chenni S. , Cannon, Bryan C. , Asirvatham, Samuel J. , Kapa, Suraj , McLeod, Christopher J. , Noseworthy, Peter A. , Asirvatham, Samuel J

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | April 21, 2016 | Volume: 9 | Issue: 5 | Pages: No page available

10.1161/circep.116.004005 | PMID 27103091 Get It

Background— Although the vast majority of mitral valve prolapse (MVP) is benign, a small subset of patients, predominantly women, with bileaflet prolapse, complex ventricular ectopy (VE), and abnormal T waves comprise the recently described bileaflet MVP syndrome. We compared findings on electrophysiological study in bileaflet MVP syndrome patients with and without cardiac arrest to identify factors that may predispose to malignant ventricular arrhythmia. Methods and Results— Fourteen consecutive bileaflet MVP syndrome patients (n=13 women; median [limits], age at index ablation, 33.8 [21.0–58.7] years; ejection fraction, 60% [45%–67%]; all ≤ moderate mitral regurgitation; n=6 with previous cardiac arrest and implantable cardioverter defibrillator shocks for ventricular fibrillation; and n=8 without implantable cardioverter defibrillator although with symptomatic complex VE) were included. The 2 groups had similar baseline echocardiographic and electrocardiographic characteristics. All patients had at least 1 left ventricular papillary or fascicular VE focus. Purkinje origin VE was identified as the ventricular fibrillation trigger in 6 of 6 cardiac arrest patients (4 from papillary muscle) and Purkinje origin of dominant VE was seen in 5 of 8 (3 from papillary muscle) nonarrest patients. Acute success was seen in 17 of 19 procedures, and a ventricular fibrillation storm occurred within 24 hours of ablation in a single patient. Repeat ablation for recurrent symptomatic arrhythmia was performed in 6 patients. At 478 (39–2099) days of follow-up, 2 cardiac arrest patients received appropriate shocks. Symptoms from VE were reduced in 12 of 14. Conclusions— Bileaflet MVP syndrome is characterized by fascicular and papillary muscle VE that triggers ventricular fibrillation. Ablation of clinically dominant VE foci improves symptoms and reduces appropriate implantable cardioverter defibrillator shocks.